KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses (2016 - 2025)

Rigel Pharmaceuticals has reported Operating Expenses over the past 16 years, most recently at $46.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 13.9% year-over-year to $46.6 million; the TTM value through Dec 2025 reached $168.8 million, up 8.85%, while the annual FY2025 figure was $168.8 million, 8.85% up from the prior year.
  • Operating Expenses for Q4 2025 was $46.6 million at Rigel Pharmaceuticals, up from $41.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $49.2 million in Q4 2022 and troughed at $32.2 million in Q2 2023.
  • A 5-year average of $39.9 million and a median of $40.7 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: increased 28.47% in 2021 and later crashed 31.25% in 2023.
  • Year by year, Operating Expenses stood at $41.8 million in 2021, then grew by 17.62% to $49.2 million in 2022, then crashed by 31.25% to $33.8 million in 2023, then grew by 21.03% to $40.9 million in 2024, then rose by 13.9% to $46.6 million in 2025.
  • Business Quant data shows Operating Expenses for RIGL at $46.6 million in Q4 2025, $41.0 million in Q3 2025, and $40.6 million in Q2 2025.